Registered title, quoted from ClinicalTrials.gov
Adjuvant TACE in HCC With High-risk Recurrence Factors
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Guangxi Medical University Cancer Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07417397, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
present with at least one high-risk factor for recurrence (such as tumor rupture; maximum tumor diameter >5 cm; multifocal tumors; microvascular invasion on postoperative pathology; Vp1/Vp2 portal vein invasion; lymph node metastasis confirmed by postoperative pathology; positive or narrow surgical margin; and Edmondson grade Ⅲ-Ⅳ differentiation).
Inclusion criterion 9
Child-Pugh class A or B7 (score 5-7);
Inclusion criterion 2
undergo hepatic angiography 4-8 weeks after surgery, with confirmation of no intrahepatic tumor staining;
Inclusion criterion 5
Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 at enrollment;
Inclusion criterion 1
diagnosis of other malignancies within the 5 years prior to enrollment;
Exclusion criterion 2
pregnant or lactating women are ineligible for participation;
Exclusion criterion 5
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07417397, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 at enrollment;
- Child-Pugh class A or B7 (score 5-7);
- having undergone radical hepatic resection at one of the study centers;
- histopathologically confirmed HCC;
- undergo hepatic angiography 4-8 weeks after surgery, with confirmation of no intrahepatic tumor staining;
- have no prior systemic anti-tumor therapy for HCC;
- have adequate organ and bone marrow function;
- estimated life expectancy >6 months;
- present with at least one high-risk factor for recurrence (such as tumor rupture; maximum tumor diameter >5 cm; multifocal tumors; microvascular invasion on postoperative pathology; Vp1/Vp2 portal vein invasion; lymph node metastasis confirmed by postoperative pathology; positive or narrow surgical margin; and Edmondson grade Ⅲ-Ⅳ differentiation).
Exclusion Criteria:
- absence of pathological confirmation of HCC;
- diagnosis of other malignancies within the 5 years prior to enrollment;
- a history of hepatic encephalopathy, liver transplantation, pleural effusion, ascites, or pericardial effusion with clinical symptoms after curative hepatectomy, as well as a history of drug allergy, active pulmonary tuberculosis, active syphilis infection, autoimmune disease, or long-term glucocorticoid use;
- participants who have experienced severe infections within 4 weeks before the first dose, or who have previously received systemic anti-tumor therapy;
- pregnant or lactating women are ineligible for participation;
- participants who are unable to comply with the treatment regimen or complete the follow-up requirements.
Quoted from ClinicalTrials.gov, NCT07417397, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07417397, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.